Search the Newsreel

Moderna doses first patient in cancer therapy trial

Moderna has initiated a Phase 1 study by dosing the first U.S. patient with mRNA-4200, an investigational cancer therapy for advanced or metastatic solid tumors. This therapy, developed in collaboration with Immatics, encodes seven common cancer antigens and will be evaluated for safety and …

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Moderna has announced that the first participant has been dosed in its Phase 1 clinical trial for mRNA-4200, an investigational tumor-targeted cancer antigen therapy. This therapy aims to induce and expand T-cell responses against multiple shared tumor targets in patients with advanced or metastatic …

Moderna Trial Tests Cancer Therapy Encoding Seven Antigens

Moderna has announced that the first U.S. participant has been dosed in its Phase 1 clinical trial for mRNA-4200, an investigational tumor-targeted cancer antigen therapy. This therapy, designed to stimulate T-cell responses against seven shared tumor targets, aims to treat advanced or metastatic solid …

YieldMax MRNA option income strategy ETF declares $0.3647 dividend

The YieldMax MRNA Option Income Strategy ETF has declared a monthly dividend of $0.3647 per share. This announcement highlights its income strategy as an exchange-traded fund.

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents held by Sanofi's unit, …

Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale

Stephen Hoge, a holder of Moderna (NASDAQ: MRNA) stock, has filed a notice for a proposed sale of up to 53,336 common shares. These shares are associated with a stock option exercise dated July 15, 2026, and the sale will be conducted through Fidelity …

Moderna Inc (MRNA) gives back 14.4% despite 36.8% four-week gain

The biotech stock’s weekly reversal complicates a broader rebound, with turnover still above recent norms.

Moderna Inc (MRNA) momentum broadens with 68.1% four-week surge

The biotechnology stock’s latest weekly close extends a sharp rebound, with strength readings firm but volume evidence not entirely uniform.

Moderna Inc (MRNA) four-week rebound reaches 42.6%

The biotechnology stock’s weekly setup remains active, with momentum readings positive but Market Dynamics confirmation still modest.

Moderna Inc (MRNA) extends rebound as four-week gain reaches 42.6%

The biotechnology stock’s weekly setup has improved, but volume evidence leaves confirmation mixed.

Moderna Inc (MRNA) rebounds 28.2% as weekly trading volume jumps

The biotech stock’s recovery has widened beyond the latest week, though pressure readings keep the signal mix from looking clean.

Moderna Inc (MRNA) jumps 28.2% in a heavy-volume weekly move

The biotechnology stock’s rebound has broadened over the past month, but Market Dynamics still points to pressure rather than clean confirmation.

Moderna Inc (MRNA) moves back into focus on heavy weekly trading

The biotech rebound now spans multiple weekly windows, but momentum confirmation remains uneven.

Moderna’s 28% week leads Healthcare on heavier volume, with pressure still unconvinced

MRNA closed at 63.96 after a sharp weekly advance, ranking first in US Healthcare and US Biotechnology, but the Sharemaestro read remains balanced as activity pressure stays negative.

Moderna Inc (MRNA) turnover jumps as four-week rebound reaches 36.4%

The biotechnology stock is back on the active-mover screen, but momentum evidence is not all one-way.

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna (MRNA) Q1 2026 Earnings Transcript

Moderna sees revenue bump from international COVID vaccine sales

Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings

Moderna Q1 2026 earnings beat on international COVID vaccine sales

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

Moderna looks outside US for growth after FDA's flu shot refusal

Earnings call transcript: Moderna sees Q2 2025 revenue drop, stock surges